Actos (Pioglitazone) for NAFLD / MASLD: Evidence, Dosing, and What to Expect

Pioglitazone is the generic name of the drug marketed as Actos, an oral thiazolidinedione (TZD) that works as a PPAR-gamma agonist. The FDA has approved it only for type 2 diabetes. Its use for nonalcoholic fatty liver disease (NAFLD), now more often called metabolic dysfunction-associated steatotic liver disease (MASLD), and for its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), is off-label. That off-label use is not fringe: pioglitazone has more randomized trial data on liver histology than any other oral diabetes or metabolic drug, and it remains part of specialty-society guidance for NASH in patients with prediabetes or type 2 diabetes.

This article is pending qualified clinical review. Nothing here should be used to select a dose or start treatment without a prescriber who has reviewed your liver biopsy or noninvasive fibrosis staging, your diabetes status, and your cardiac and bone health history.

The core answer, in one place: Pioglitazone is FDA-approved for type 2 diabetes and used off-label for biopsy-confirmed NASH, most often in adults who also have prediabetes or type 2 diabetes; the pivotal randomized trial in this area (the PIVENS trial, published in the New England Journal of Medicine in 2010) reported that a meaningfully larger share of pioglitazone-treated, non-diabetic NASH patients achieved histologic resolution of steatohepatitis compared with placebo, with a statistically significant benefit on fibrosis stage that vitamin E did not show in the same trial. As of 2024, resmetirom (Rezdiffra) is the only drug with an FDA-approved indication specifically for MASH with moderate to advanced fibrosis, which changes where pioglitazone fits but does not remove its role in patients with concurrent diabetes or where cost is a barrier.

What MASLD and MASH are, and why this drug is relevant

MASLD (the term that replaced NAFLD in 2023 nomenclature revisions) describes excess fat accumulation in the liver not explained by heavy alcohol use. It is common in adults with obesity, insulin resistance, and type 2 diabetes. A subset of people with MASLD develop MASH, in which fat accumulation is accompanied by liver cell injury, inflammation, and fibrosis that can progress toward cirrhosis over years.

Insulin resistance is central to how MASLD develops and worsens. Excess fatty acid delivery to the liver, driven by resistance to insulin's normal signaling in fat and muscle tissue, drives fat accumulation and oxidative stress in liver cells. Pioglitazone's PPAR-gamma agonism improves insulin sensitivity, shifts fat storage away from the liver and visceral depots, and raises adiponectin, a hormone that itself has anti-inflammatory and insulin-sensitizing effects in the liver. This is a plausible and reasonably well-studied mechanism, not a settled cure; mechanism explains why the drug might help, not how much it will help any individual patient.

What the trial evidence actually shows, and its limits

The most frequently cited trial in this area is the PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-Diabetic Patients with Nonalcoholic Steatohepatitis), a multicenter randomized controlled trial published in NEJM in 2010. As commonly reported in the literature, PIVENS found that a meaningfully higher proportion of pioglitazone-treated patients achieved the trial's primary histologic endpoint compared with placebo, along with a statistically significant improvement in fibrosis stage that the vitamin E arm did not achieve. Participants gained weight on pioglitazone, several kilograms on average over the roughly two-year trial period.

A separate, earlier placebo-controlled study by Belfort and colleagues, also published in NEJM, examined pioglitazone in patients with type 2 diabetes or impaired glucose tolerance and biopsy-proven NASH, and is generally cited as supporting benefit in that diabetic population as well.

Two evidence cautions are worth stating plainly. First, the exact percentages, confidence intervals, and p-values attributed to PIVENS and related trials in older secondary sources are not independently re-verified in this draft; a clinician relying on precise numeric outcomes for patient counseling should pull the original NEJM publication rather than a secondary summary. Second, a widely circulated statement attributing a specific direct quotation to the 2018 AASLD practice guidance on NAFLD ("pioglitazone can be used to treat steatohepatitis...") could not be verified against a confirmed source in this review and has been removed rather than repeated as a verbatim quote. The general position, that specialty guidance has supported pioglitazone as an option for biopsy-proven NASH in select patients, is consistent with how the drug is used in practice, but the exact wording should not be treated as an authoritative quotation until an editor confirms it against the primary guideline document.

Separately, a French national cohort study and the PROactive cardiovascular outcomes trial are the usual sources cited for pioglitazone's bladder cancer and fracture signals, discussed below. The specific hazard ratios attributed to these studies in earlier drafts of this article are flagged for the same reason: they should be checked against the original publications before being presented to a patient as precise numbers, not treated as verified here.

How pioglitazone compares to resmetirom and GLP-1 agents

The regulatory landscape shifted substantially in March 2024, when the FDA granted accelerated approval to resmetirom (Rezdiffra) for adults with MASH and moderate to advanced fibrosis (stages F2 to F3), the first drug with a label specifically for this indication. That regulatory record can be checked directly on the FDA's application database (FDA Application 217785). This is FDA-approved-indication evidence, the strongest tier available, and it sits above pioglitazone's off-label trial evidence in the hierarchy that should guide practice for patients who fit resmetirom's approved population and can access it.

GLP-1 receptor agonists, including liraglutide and semaglutide, have also shown reductions in liver fat and, in smaller trials, histologic improvement, though evidence for fibrosis benefit specifically has been more mixed across studies than for steatohepatitis resolution. Larger phase 3 MASH trials of semaglutide and tirzepatide have been reported at hepatology conferences and in preliminary form; final peer-reviewed results and any regulatory decisions should be checked directly rather than assumed, since this is an actively moving evidence base as of 2025.

Put simply: resmetirom now has the strongest, most current evidence tier (FDA approval) for MASH with significant fibrosis. GLP-1 agents have a growing trial base and dual metabolic benefit. Pioglitazone has the longest track record and the lowest cost, and its evidentiary edge is specifically fibrosis-stage improvement in a large, mature randomized trial, plus a documented role in patients who also need glycemic control. None of these facts make pioglitazone obsolete; they narrow which patient should reasonably be offered it first.

Decision framework: does pioglitazone make sense for this patient?

Use this as a structured starting point for a clinical conversation, not a substitute for individualized dosing or diagnosis.

If two or more "avoid" or "avoid or use with caution" rows apply, that is a signal to bring an alternative agent to the conversation before pioglitazone, not after a trial-and-failure period.

What a typical off-label protocol looks like (not individualized dosing advice)

Published trial protocols and common off-label prescribing patterns generally describe pioglitazone started at a low dose and titrated upward over weeks, most often to 30 mg once daily, sometimes to 45 mg once daily if tolerated, with a treatment horizon of at least 18 to 24 months before histologic reassessment, because that is roughly the duration used in the pivotal trial before liver biopsy was repeated. This general description is not a dosing instruction for any individual reader. Actual starting dose, titration pace, and duration must be set by a prescriber based on kidney and liver function, heart failure risk, bone health, and concurrent medications.

Baseline evaluation before starting typically includes a liver biopsy or a validated noninvasive fibrosis score, fasting glucose and HbA1c, a lipid panel, weight and blood pressure, and a baseline urinalysis. Ongoing monitoring generally tracks weight and signs of fluid retention at each visit, glycemic markers periodically, liver enzymes, and an annual urinalysis given the bladder cancer caution described below. Postmenopausal women on longer-term therapy are often considered for a baseline bone density scan given the fracture signal associated with this drug class.

Side effects that matter specifically in this population

Weight gain. Pioglitazone has a consistent, dose-related association with weight gain in trial populations, which is an unfavorable trade-off in a disease driven by excess adiposity. Prescribers commonly set a threshold, several kilograms above baseline, at which continuing therapy, adding a GLP-1 agent, or stopping the drug is reconsidered.

Fluid retention and heart failure. PPAR-gamma agonism increases sodium and water reabsorption in the kidney, which can produce peripheral edema and, in susceptible patients, precipitate or worsen heart failure. This is why the drug is contraindicated in advanced heart failure and used cautiously, if at all, in milder heart failure.

Bladder cancer. Regulatory bodies, including the FDA, have carried a bladder cancer caution on pioglitazone's label since 2011 based on epidemiologic data suggesting a modest increase in risk with longer-term, higher cumulative-dose use. The magnitude of that risk reported in specific cohort studies is not independently re-verified here and should be checked against the primary study before being quoted as a precise number. Annual urinalysis is a reasonable monitoring step, and any visible blood in the urine warrants prompt urology evaluation.

Bone fractures in women. Long-term outcome trials of pioglitazone, most notably PROactive, are the usual basis for an increased fracture risk signal in women. As with the bladder cancer figure, the exact hazard ratio commonly cited for this finding should be verified against the primary trial publication rather than repeated as settled without that check.

Liver enzymes. Pioglitazone does not appear to cause liver injury in the way some other drugs do; in fact, ALT and AST commonly improve rather than worsen during treatment in trial populations, and the drug is not generally considered contraindicated in liver disease short of active liver failure. This is a reassurance worth stating clearly, since patients starting a drug for a liver condition often worry about liver-related side effects specifically.

What is established, what is plausible, and what is not

Established: Pioglitazone is FDA-approved for type 2 diabetes, not for MASLD or MASH. It carries a well-documented mechanistic rationale (PPAR-gamma agonism, improved insulin sensitivity) for benefit in fatty liver disease. Weight gain, fluid retention, and a bladder cancer caution are documented, labeled concerns for the drug class generally. Resmetirom, not pioglitazone, is the only agent with a current FDA-approved indication specifically for MASH with significant fibrosis.

Plausible but not fully settled from the material available here: The precise magnitude of histologic benefit, fibrosis improvement, bladder cancer risk, and fracture risk attributed to specific named trials in circulation online. These figures are widely repeated but were not independently reverified against primary publications in this draft, and a clinician should not present them to a patient as exact, sourced numbers without that check.

Not established: That pioglitazone plus a GLP-1 receptor agonist produces additive liver benefit beyond what either drug achieves alone; that pioglitazone is superior to resmetirom in patients who meet resmetirom's approved population; and any individualized claim about how much benefit a specific patient will see, since trial averages do not predict individual response.

Coverage and cost, as of 2025

Because pioglitazone's only FDA-approved indication is type 2 diabetes, insurance coverage for MASLD or MASH use is off-label and inconsistent across payers. Patients with a documented type 2 diabetes diagnosis typically face few coverage barriers because the prescription fits the approved indication. Patients without diabetes may need a prior authorization or medical necessity letter, and coverage decisions vary by plan. Generic pioglitazone has historically been inexpensive at retail pharmacies, often well under the cost of a typical specialty-drug copay, which makes cash-pay a realistic option for many patients regardless of insurance outcome. Exact current pricing should be checked at the pharmacy at the time of the prescription, since retail generic prices shift.

Questions worth asking your prescriber

• Do I have biopsy-confirmed or imaging-suggested NASH, and what fibrosis stage, and does that change whether resmetirom fits better than pioglitazone?
• Do I have prediabetes or type 2 diabetes, since that changes the risk-benefit calculation for this drug specifically?
• What is my personal fracture risk, and do I need a bone density scan before starting?
• What weight gain would trigger stopping or changing the plan?
• How will bladder cancer risk be monitored, and what symptoms should prompt an urgent call?
• How long will we wait before reassessing liver fibrosis, and with what test?

When to seek urgent care

New or worsening shortness of breath, rapid weight gain with swelling in the legs or abdomen, visible blood in the urine, or signs of liver failure such as jaundice, confusion, or severe abdominal swelling are not things to manage by adjusting a MASLD medication at home. These warrant prompt medical evaluation, not a wait-and-see approach tied to a routine follow-up appointment.

References

• U.S. Food and Drug Administration, drug application record for resmetirom (Rezdiffra): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217785
• U.S. Food and Drug Administration, Actos (pioglitazone hydrochloride) prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf

This draft removed several previously cited PubMed identifiers because they could not be independently verified as pointing to the correct paper during this review. A qualified reviewer should re-source the specific trial statistics (PIVENS histologic outcomes, the Belfort trial, the bladder cancer cohort study, the PROactive fracture finding, and the resmetirom and semaglutide trial results) directly from PubMed or the original journals before this article is finalized, and restore precise citations only where confirmed accurate.